MiNK Therapeutics (NASDAQ:INKT) Earns “Buy” Rating from HC Wainwright

MiNK Therapeutics (NASDAQ:INKT)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $35.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 341.92% from the company’s previous close.

MiNK Therapeutics Price Performance

Shares of MiNK Therapeutics stock opened at $7.92 on Tuesday. MiNK Therapeutics has a 1 year low of $4.56 and a 1 year high of $19.00. The firm’s 50-day moving average is $8.91 and its two-hundred day moving average is $7.75. The stock has a market cap of $31.39 million, a price-to-earnings ratio of -2.03 and a beta of 0.16.

MiNK Therapeutics (NASDAQ:INKT) last issued its earnings results on Tuesday, March 18th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.12). On average, equities analysts expect that MiNK Therapeutics will post -2.75 earnings per share for the current year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.